Adverse Events in Healthy Individuals and MDR-TB Contacts Treated with Anti-Tuberculosis Drugs Potentially Effective for Preventing Development of MDR-TB: A Systematic Review

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Langendam, Miranda W ^a   Tiemersma, Edine W ^a,b   van der Werf, Marieke J ^a,b,c   Sandgren, Andreas ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^c EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; CIPROFLOXACIN; CLARITHROMYCIN; ETHAMBUTOL; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PLACEBO; PYRAZINAMIDE; RIFABUTIN; TUBERCULOSTATIC AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACNE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARM PAIN; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOATING; CONSTIPATION; CONTACT EXAMINATION; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG WITHDRAWAL; DRY EYE; DYSPEPSIA; EDEMA; EMBASE; ERYTHEMA; EUPHORIA; FAINTNESS; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DISEASE; HEPATITIS; HICCUP; HUMAN; HYPERURICEMIA; INSOMNIA; KERATODERMA; LIMB PAIN; LOOSE FECES; MEDLINE; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; NOSE OBSTRUCTION; OTALGIA; PARESTHESIA; PHARYNGITIS; PHLEBITIS; PRURITUS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHINITIS; SAMPLE SIZE; SIDE EFFECT; SORE THROAT; STOMACH PAIN; SYSTEMATIC REVIEW; TACHYCARDIA; TASTE DISORDER; TOOTH PAIN; TREATMENT DURATION; URINE INCONTINENCE; VAGINITIS; VERTIGO; VISUAL DISORDER; VOLUNTEER; VOMITING; WEAKNESS; XEROSTOMIA;

ANTITUBERCULAR AGENTS; BIAS (EPIDEMIOLOGY); CONTACT TRACING; HEALTH; HUMANS; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84872230768     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053599     Document Type: Review

References (49)

1. World Health Organization (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: WHO.
2. Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, et al. (2011) Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 377 (9760) (): 147-152.
3. Kritski AL, Marques MJ, Rabahi MF, Vieira MA, Werneck-Barroso E, et al. (1996) Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 153 (1) (): 331-335.
4. Teixeira L, Perkins MD, Johnson JL, Keller R, Palaci M, et al. (2001) Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 5 (4) (): 321-328.
5. Grandjean L, Crossa A, Gilman RH, Herrera C, Bonilla C, et al. (2011) Tuberculosis in household contacts of multidrug-resistant tuberculosis patients. Int J Tuberc Lung Dis 15 (9) (): 1164-i, 1164-1269, i.
6. Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, et al. (2002) Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 109 (5) (): 765-771.
7. Attamna A, Chemtob D, Attamna S, Fraser A, Rorman E, et al. (2009) Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort. Thorax 64 (3) (): 271.
8. Bayona J, Chavez-Pachas AM, Palacios E, Llaro K, Sapag R, et al. (2003) Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 7 (12 Suppl 3) (): S501-S509.
9. Mohammadi A, Nassor ZS, Behlim T, Mohammadi E, Govindarajan R, et al. (2008) Epidemiological and cost analysis of multidrug-resistant tuberculosis in Oman. East Mediterr Health J 14 (6) (): 1240-1245.
10. Vella V, Racalbuto V, Guerra R, Marra C, Moll A, et al. (2011) Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting. Int J Tuberc Lung Dis 15 (9) (): 1170-i, 1170-1175, i.
11. Singla N, Singla R, Jain G, Habib L, Behera D, (2011) Tuberculosis among household contacts of multidrug-resistant tuberculosis patients in Delhi, India. Int J Tuberc Lung Dis 15 (10) (): 1326-1330.
12. Horn DL, Hewlett D Jr, Alfalla C, Peterson S, Opal SM, (1994) Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. New Engl J Med 330 (17) (): 1241.
13. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, et al. (1997) Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis 24 (6) (): 1264-1265.
14. Barry PM, Gardner TJ, Funk E, Oren E, Field K, et al. (2012) Multistate Outbreak of MDR TB Identified by Genotype Cluster Investigation. Emerg Infect Dis 18 (1) (): 113-116.
15. Oeltmann JE, Varma JK, Ortega L, Liu Y, O'Rourke T, et al. (2008) Multidrug-resistant tuberculosis outbreak among US-bound Hmong refugees, Thailand, 2005 (2008) Emerg Infect Dis 14 (11): 1715-1721.
16. American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 49 (RR-6) (): 1-51.
17. National Institute for Health and Clinical Excellence (NICE) (2011) NICE clinical guideline 117: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: National Institute for Health and Clinical Excellence.
18. Migliori GB, Zellweger JP, Abubakar I, Ibraim E, Caminero JA, et al. (2012) European union standards for tuberculosis care. Eur Respir J 39 (4) (): 807-19.
19. World Health Organization (2008) Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update, 2008. [WHO/HTM/TB/2008.402]. Geneva: WHO.
20. World Health Organization (2011) Guidelines for the programmatic management of drug-resistant tuberculosis- 2011 update. [WHO/HTM/TB/2011.6]. Geneva: WHO.
21. National Tuberculosis Controllers Association and CDC (2005) Guidelines for the investigation of contacts of persons with infectious tuberculosis. MMWR Recomm Rep 54 (RR-15) (): 1-47.
22. Villarino ME, Dooley SW, Geiter LJ, Castro KG, Snider DE, et al. (1992) Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm Rep 41 (RR-11) (): 61-71.
23. Van der Werf MJ, Langendam MW, Sandgren A, Manissero D, (2012) Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int J Tuberc Lung Dis 16 (3) (): 288-296.
24. European Centre for Disease Prevention and Control (ECDC) (2012) ECDC Guidance: Management of contacts of MDR TB and XDR TB patients. Stockholm: ECDC.
25. Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available: http://handbook.cochrane.org/. Accessed 2012 Dec 14.
26. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151 (4) (): W65-W94.
27. Golder S, McIntosh HM, Duff S, Glanville J, (2006) for the Centre for Reviews and Dissemination and UK Cochrane Centre Search Filters Design Group UoYU (2006) Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. Health Information and Libraries Journal 23: 3-12.
28. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M, (2002) Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 167 (2) (): 131-136.
29. Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP, (2005) High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 26: 462-464.
30. Wells GA, Shea BJ, O'Connell D, Peterson J, Welch V, et al. (2011) The Newcastle Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Lancet Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed 2012 Dec 14.
31. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, et al. (2008) What is "quality of evidence" and why is it important to clinicians? BMJ 336 (7651) (): 995-998.
32. Amsden GW, Graci DM, Cabelus LJ, Hejmanowski LG, (1999) A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections. Chest 116: 115-119.
33. Chien SC, Wong FA, Fowler CL, Callery-D'Amico SV, Williams RR, et al. (1998) Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrobial Agents and Chemotherapy 42 (4) (): 885-888.
34. Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, et al. (1997) Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrobial Agents and Chemotherapy 41 (10) (): 2256-2260.
35. Chow AT, Fowler C, Williams RR, Morgan N, Kaminski S, et al. (2001) Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrobial Agents and Chemotherapy 45 (7) (): 2122-2125.
36. Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF, (2006) Effects of three fluoroquinolones on QT analysis after standard treatment courses. ANE 11 (1) (): 52-56.
37. Ayalasomayajula S, Yeh CM, Vaidyanathan S, Flannery B, Dieterich HA, et al. (2008) Effects of aliskiren, a direct Renin inhibitor, on cardiac repolarization and conduction in healthy subjects. J Clin Pharmacol 48: 799-811.
38. Burkhardt O, Borner K, Stass H, Beyer G, Allewelt M, et al. (2002) Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scan J Infect Dis 34: 898-903.
39. Peeters M, Janssen K, Kakuda TN, Scholler-Gyure M, Lachaert R, et al. (2008) Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers. Annals of Pharmacotherapy 42: 757-765.
40. Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, et al. (1999) Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrobial agents and Chemotherapy 43 (11) (): 2793-2797.
41. Guay DR, Opsahl JA, McMahon FG, Vargas R, Matzke GR, et al. (1992) Safety and pharmacokinetics of multiple doses of intravenous ofloxacin in healthy volunteers. Antimicrobial Agents and Chemotherapy 36 (2) (): 308-312.
42. Marier JF, Ducharme MP, DiMarco M, Di Spirito M, Morelli G, et al. (2006) Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediateand extended-release formulations in healthy subjects. Clinical Therapeutics 28 (12) (): 2070-2080.
43. Stein GE, Flor SC, Beals BS, (1991) Safety of multiple doses of ofloxacin in healthy volunteers. Drugs Exptl Clin Res XVII (10-11): 525-529.
44. Ford SL, Chen YC, Lou Y, Borland J, Min SS, et al. (2008) Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Antimicrobial Agents and Chemotherapy 52 (2) (): 534-538.
45. Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, et al. (2004) Indinavir and Rifabutin Drug Interactions in Healthy Volunteers. J Clin Pharmacol 44 (3) (): 305-313.
46. Van Saene HK, Lemmens SE, van Saene JJ, (1988) Gut decontamination by oral ofloxacin and ciprofloxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 22 Suppl C: 127-34.
47. Zhang L, Li JT, Lu Y, Li MN, Zhang YL, et al. (2002) Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects. Acta Pharmcol Sin 4: 381-384.
48. Palmero D, Ritacco V, Ruano S, Ambroggi M, Cusmano L, et al. (2005) Multidrug-resistant tuberculosis outbreak among transvestite sex workers, Buenos Aires, Argentina. Int J Tuberc Lung Dis 9 (10) (): 1168-1170.
49. Danan G, Pessayre D, Larrey D, Benhamou JP, (1981) Pyrazinamide fulminant hepatitis: an old hepatotoxin strikes again. Lancet 318 (8254) (): 1056-7.